To clarify the molecular basis of penile erection at the human level and distinguish the mechanisms underlying vasculogenic and post-radical prostatectomy (RP) erectile dysfunction (ED) subtypes.
Introduction
Erectile dysfunction (ED) affects >18 million men in the USA and is predicted to rise to 322 million men worldwide by the year 2025 [1] . Vasculogenic ED involves~80% of ED cases and is commonly associated with vascular disorders such as hypertension, cardiovascular disease, diabetes mellitus, smoking and dyslipidaemia [2] . Studies in men with vasculogenic ED have shown decreased endotheliummediated and neurogenic relaxation, increased adrenergic contraction, apoptosis and fibrosis, and decreased smooth muscle/collagen ratio in the erectile tissue [3, 4] , and increased oxidative stress in the peripheral blood [5] . Neurogenic ED represents 10-19% of all causes of ED and, at the peripheral level, is mostly a consequence of pelvic surgeries such as radical prostatectomy (RP) [6] . Post-RP ED is typically attributed to injury to the cavernous nerve [2] , although damage to accessory or aberrant pudendal arteries can add a vasculogenic component [7] . Penile denervation causes decreased neurogenic relaxation, increased adrenergic contraction, apoptosis and fibrosis in human erectile tissue [3, 4] .
Regardless of ED aetiology, phosphodiesterase type 5 (PDE5) inhibitors are commonly prescribed as first-line ED treatment; however, clinical trials with PDE5 inhibitors have not shown that they have a major impact on erectile function recovery after RP, in contrast to their more beneficial effect in vasculogenic ED [8] ; thus, the management of post-RP ED requires the implementation of adjunctive neuroprotective or neuroregenerative therapies that will be defined and developed by ongoing investigative studies of neurogenic molecular pathways.
The nitric oxide (NO)-dependent cGMP pathway is the major signalling mechanism responsible for smooth muscle relaxation in the corpora cavernosa. The RhoA/Rhoassociated protein kinase (ROCK) contractile pathway closely interacts with the NO pathway and contributes to the regulation of erection responses [2] ; however, at the human level, the mechanism of ED and, specifically, the mechanisms underlying vasculogenic and post-RP ED subtypes are unclear. Clarifying the molecular basis of penile erection at the human level may serve not only to distinguish ED subtypes but also to guide further cause-specific therapies for ED.
In the present study, we hypothesized that oxidative stress, dysregulation of the NO pathway, and derangements in PDE5 signalling and the RhoA/ROCK pathway are major determinants of ED in men. We performed an extensive molecular evaluation of these major erection regulatory factors in erectile tissue of men with vasculogenic and post-RP ED.
Patients and Methods

Patient Population and Tissue Collection
Tissue collection and clinical history review were performed with approval from the institutional review board of the Johns Hopkins Medical Institutions, and written informed consent was obtained from all patients. A total of 22 human erectile tissue samples were selected. Erectile tissue was obtained from men without histories of ED (Sexual Health Inventory for Men [SHIM] score >21 and verified by penile duplex ultrasonography) who underwent penile surgery for Peyronie's disease (control group) and with ED (SHIM score <21) who underwent penile prosthesis implantation. ED patients were categorized based on ED aetiology: vasculogenic ED and ED secondary to RP (post-RP ED), the latter being used to model neurogenic ED. For the vasculogenic group, we selected patients without diabetes mellitus (which is associated with both vasculogenic and neurogenic ED), and for the post-RP ED group, we selected patients without diabetes mellitus and cardiovascular disease who developed ED only after undergoing RP. All patients in vasculogenic and post-RP ED groups who underwent penile prosthesis surgery had PDE5 inhibitor failures and the therapies were stopped at least 3 months before penile implantation and tissue collection, lessening the possibility of a PDE5 inhibitor effect on PDE5 protein expression. Cavernous nerve-sparing surgery was reportedly performed in seven out of nine patients with post-RP ED, of whom five had both cavernous nerves spared; however, we assumed some element of neuropraxia had occurred in these patients. The tissues were collected at a mean (range) of 73.8 AE 12.8 (21-130) months after RP surgery. Patient characteristics are summarized in Table 1 . All penile prosthesis surgeries were performed by the same surgeon (A.L.B.). Penile erectile tissue samples (0.5-1 cm) were obtained bilaterally from the proximal corpus cavernosum, at a region separate from fibrotic tunica in patients with Peyronie's disease. Samples were collected during surgery, immediately placed in cold saline, and then frozen in liquid nitrogen for molecular studies.
Western Blot
Penile tissue was homogenized as reported previously [9] [10] [11] . NO synthases (NOSs) were partially purified as described previously [9] [10] [11] . Membranes with partially purified NOSs were probed with anti-phospho-neuronal (n)NOS (Ser-1412) antibody (polyclonal rabbit, kindly provided by Dr Solomon Snyder, Johns Hopkins University, Baltimore, MD, USA) at 1:6 000 dilution or anti-phospho-endothelial (e)NOS (Ser-1177) antibody (polyclonal rabbit; Cell Signaling Technology, Beverly, MA, USA) at 1:450 dilution (for phospho-nNOS and phospho-eNOS analyses) [9] . After probing for phosphoforms, membranes were stripped and probed with antibodies against nNOS (polyclonal rabbit, 1:9 000 dilution; Dr Solomon Snyder) or eNOS (monoclonal mouse, 1:500 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA,). phospho-nNOS (Ser-1412) and phospho-eNOS (Ser-1177) densities were normalized relative to those of nNOS and eNOS, respectively, in partially purified samples. Dimeric and monomeric forms of nNOS and eNOS were measured by low temperature SDS electrophoresis, as described previously [9-11], using anti-nNOS antibody (polyclonal rabbit, 1:1 000 dilution; Cell Signaling Technology) and anti-eNOS antibody (monoclonal mouse, 1:500 dilution; Santa Cruz Biotechnology). For analysis of total nNOS (polyclonal rabbit antibody, 1:1 000 dilution; Cell Signaling Technology), total eNOS (monoclonal mouse antibody, 1:500 dilution; Santa Cruz Biotechnology), ROCKa (monoclonal mouse antibody, 1:1 000 dilution; BD Transduction Laboratories, San Jose, CA, USA), ROCKb (monoclonal mouse antibody, 1:1 000 dilution; Santa Cruz Biotechnology), phospho-myosin phosphatase target subunit 1 (MYPT1; Thr-696; polyclonal rabbit antibody, 1:1 000 dilution; Santa Cruz Biotechnology), PDE5 (monoclonal mouse antibody, 1:450 dilution; BD Transduction Laboratories), 4-hydroxy-2-nonenal (4-HNE; polyclonal rabbit antibody, 1:2 000 dilution; Alpha Diagnostic International, San Antonio, TX, USA), phospho-Akt (Ser-473; polyclonal rabbit antibody, 1:1 000 dilution; Cell Signaling Technology), and Akt (polyclonal rabbit antibody, 1:1 000 dilution; Cell Signaling Technology), a separate set of homogenates (70-100 lg) was used without purification, and standardized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH; monoclonal mouse antibody, 1:1 000 dilution; Santa Cruz Biotechnology) [9] [10] [11] . Band densities were quantified using NIH Image 1.29. The analysis of 4-HNE was a densitometric composite of all proteins in each lane. nNOS and eNOS uncoupling were represented inversely as a ratio of functional nNOS and eNOS dimers to non-functional nNOS and eNOS monomers, respectively. The ratio was determined in terms of arbitrary units and expressed relative to the ratio for controls.
Statistical Analysis
Data were expressed as means AE SEM [12] . Statistical analysis was performed using a modified Student's t-test. P values <0.05 were taken to indicate statistical significance.
Results
Phosphorylation of nNOS on its stimulatory (Ser-1412) regulatory site was decreased (P < 0.05) in vasculogenic ED erectile tissue and increased (P < 0.05) in post-RP ED erectile tissue, compared with erectile tissue in the control group (Fig. 1A) . Protein expression of total nNOS was decreased (P < 0.05) in post-RP ED erectile tissue, and not changed in vasculogenic ED erectile tissue, compared with the control group (Fig. 1B) .
Phosphorylation of eNOS on its stimulatory (Ser-1177) regulatory site was decreased (P < 0.05) in vasculogenic ED erectile tissue and not changed in post-RP ED erectile tissue, compared with erectile tissue in the control group ( Fig. 2A) . Similarly, Akt phosphorylation on Ser-473, which directly regulates phospho-eNOS (Ser-1177) expression [13] , was reduced (P < 0.05) in vasculogenic ED erectile tissue and not changed in post-RP ED erectile tissue, compared with the control group (Fig. 2B ). Protein expression of total eNOS was similarly decreased (P < 0.05) in vasculogenic ED erectile tissue, and not changed in post-RP ED erectile tissue, compared with erectile tissue in the control group (Fig. 2C ).
The ratio of nNOS dimer (functional nNOS)/monomer (nonfunctional nNOS) was decreased (P < 0.05) in post-RP ED erectile tissue, and not changed in vasculogenic ED erectile tissue, compared with erectile tissue in the control group (Fig. 3A) . The ratio of eNOS dimer (functional eNOS)/ monomer (non-functional eNOS) was decreased (P < 0.05) in vasculogenic ED erectile tissue, and not changed in post-RP ED erectile tissue, compared with the control group (Fig. 3B ).
Protein expression of 4-HNE, a marker of oxidative stress [11], was increased (P < 0.05) in both vasculogenic and post-RP ED erectile tissues, compared with the control group (Fig. 4) .
Protein expression of phospho-MYPT1 (Thr-696), reflecting RhoA/ROCK activity [14] , was increased (P < 0.05) in vasculogenic ED erectile tissue, and not changed in post-RP ED erectile tissue, compared with erectile tissue in the control group (Fig. 5A ). Protein expressions of ROCKa and ROCKb in vasculogenic and post-RP ED erectile tissues did not differ from values in the control group (Fig. 5B,C) .
Protein expression of PDE5 was increased (P < 0.05) in vasculogenic ED erectile tissue and decreased (P < 0.05) in post-RP ED erectile tissue compared with erectile tissue in the control group (Fig. 6A) . Protein expression of a-smooth muscle actin, an indicator of smooth muscle content [15] , was not different in post-RP ED or vasculogenic ED erectile tissue, compared with the control group (Fig. 6B) . molecular profiles for vasculogenic and post-RP ED suggest there are distinct molecular mechanisms for these ED subtypes: vasculogenic ED involves decreased total eNOS protein expression, decreased eNOS and nNOS phosphorylation on their activation sites (Ser-1177 and Ser-1412, respectively), uncoupled eNOS, upregulated PDE5 protein expression, and increased ROCK activity, while post-RP ED involves decreased total nNOS protein expression, increased nNOS phosphorylation on its activatory site (Ser-1412), uncoupled nNOS, and downregulated PDE5 protein expression. Common mechanisms for both vasculogenic and post-RP ED include increased oxidative stress in the erectile tissue, conceivably originating in some part from dysfunctional, uncoupled, eNOS and nNOS.
The major molecular mechanisms underlying the function of constitutive NOS isoenzymes are phosphorylation and uncoupling. Phosphorylation of eNOS and nNOS on activatory sites (Ser-1177 and Ser1412, respectively) activate the enzyme's catalytic functions by reducing their calcium requirement and facilitating electron transfer [16, 17] . This phospho-modification on both constitutive NOS isoenzymes lasts longer than the short-term calcium transient, contributing to both the initiation and maintenance phases of penile erection [13] [14] [15] [16] [17] [18] . Functional dimerization of NOSs is required for NO-producing activity of the enzymes. Under pathological conditions resulting in a loss of the functional enzyme's dimerization, NOSs can transform into prooxidants, generating predominantly superoxide anion rather than NO ('NOS uncoupling') [19, 20] . In the present study, we found that erectile tissue of men with vasculogenic ED exhibited downregulated phospho-eNOS (Ser-1177), conceivably through downregulation of its main regulatory Akt pathway [13] , and also downregulated phospho-nNOS (Ser-1412), implying the impairment of both NOS isoenzymes involved in vasodilation [20, 21] ; a further decrease in endothelial NO bioavailability was achieved by a loss of functional eNOS dimerization. By contrast, in post-RP ED erectile tissue, nNOS phosphorylation on Ser-1412 was increased and nNOS was uncoupled. The latter data mimic our recent findings in the rat penis 3 days after cavernous nerve damage, which, similarly to men with post-RP ED, showed increased nNOS phosphorylation on Ser-1412 and nNOS uncoupling [9] . While the mechanism of increased nNOS phosphorylation on its activation site in the neuropathic erectile tissue is unknown, it conceivably indicates a deleterious effect of overactivated nNOS, shown previously in the central and peripheral nervous systems [22, 23] ; overactivated, but uncoupled, nNOS further contributes to decreased NO bioavailability. In line with our findings, nNOS uncoupling has recently been demonstrated in the major pelvic ganglia, the site of cavernous nerve origin, of rats following cavernous nerve damage [24] . The precise mechanism by which nNOS and eNOS become uncoupled is unclear but may be related to oxidation of a critical NOS cofactor tetrahydrobiopterin (BH4), depletion of the NOS substrate L-arginine, or Sglutathionylation of NOSs [25, 26] . Downregulation of eNOS and nNOS protein expressions in vasculogenic and post-RP ED, respectively, conceivably contributes to a long-term decrease in NO bioavailability.
4-HNE
Oxidative stress has an important role in the pathogenesis of ED, shown previously in both animal and human ED studies [10, 11] . In the present study, we confirmed these previous findings and showed that increased oxidative stress (4-HNE expression) is common to both vasculogenic and neurogenic ED. 4-HNE, a marker of oxidative stress, is an end-product of lipid peroxidation which binds to lysine, cysteine and histidine, causing the modification and malfunction of multiple proteins [11] . It is conceivable that dysfunctional, uncoupled eNOS and nNOS in the erectile tissue of men with vasculogenic and post-RP ED, respectively, are sources of oxidative stress. Further studies, measuring other markers of oxidative stress, such as nitrotyrosine, and superoxide itself, would conceivably further substantiate increased oxidative stress in the erectile tissue of the two patient groups.
In vascular smooth muscle cells, including those within the penis, an inverse functional relationship exists between the NO/cGMP/PKG and RhoA/ROCK contractile signalling pathways. In the rat penis, RhoA/ROCK suppresses eNOS gene expression and activity and erectile function [27] . The RhoA/ROCK signalling pathway inhibits MYPT1 activity by phosphorylating the regulatory subunit of myosin light chain phosphatase at Thr-696, promoting smooth muscle contraction at low calcium levels [13] . In the present study, we showed upregulation of the RhoA/ROCK pathway in erectile tissue of men with vasculogenic ED, conceivably further contributing to decreased vasorelaxation and ED. While the mechanism for RhoA/ROCK upregulation is not known, decreased NO signaling may increase ROCK activity, as shown in other vascular tissues [28, 29] . Several animal studies showed that inhibition of the RhoA/ROCK pathway potentiated erectile function in vasculogenic ED associated with diabetes, hypertension and aging [27] . Increased RhoA/ ROCK activity in the erectile tissue of men with vasculogenic ED may suggest that treating this patient population with RhoA/ROCK inhibitors may improve the effect of PDE5 inhibitors in the long term. In contrast to vasculogenic ED, post-RP ED is not associated with aberrant RhoA/ROCK molecular signalling. Our findings are in line with a study showing that ROCK activity was increased in the rat major pelvic ganglia shortly after cavernous nerve injury, but unchanged at later times [24] .
Human studies indicate that ED originating from post-RP ED is less successfully treated with PDE5 inhibitors compared with ED of vasculogenic origin [8] . We hypothesized that the lack of erection ability enhancement by PDE5 inhibitors in post-RP ED patient groups may relate to decreased PDE5 protein expression in the erectile tissue. Indeed, we found decreased protein expression of PDE5 in the erectile tissue of men with post-RP ED. Our results are consistent with previous studies in rats, which demonstrated reduced PDE5 mRNA and protein levels in the penis after cavernous nerve injury [30] . Because the presence of functional, inhibitable PDE5 is required to enhance erectile function in response to PDE5 inhibitors, our findings may partially explain why men with post-RP ED are refractory to PDE5 inhibitor treatment. In line with our findings, a recent study showed that neurogenic relaxation in human corpus cavernosum strips from men with vasculogenic ED, but not post-RP ED, was potentiated by the PDE5 inhibitor tadalafil [31] . By the same logic, increased PDE5 protein expression in the erectile tissue of men with vasculogenic ED may allow a greater level of inhibition by PDE5 inhibitors, resulting in a better erectile response. PDE5 protein expression does not appear to be influenced by smooth muscle content in the erectile tissue, as a-smooth muscle actin, expressed in vascular smooth muscle cells [32] , was not affected in any of the patient groups. While the mechanism of PDE5 upregulation in the erectile tissue of men with vasculogenic ED is not known, it is conceivable that upregulated RhoA/ROCK signalling augments PDE5 activity, as shown previously in gastric smooth muscle cells [33] . By contrast, decreased protein expression of PDE5 in the erectile tissue of men with post-RP ED is conceivably a consequence of severely impaired NO signalling; downregulated NOS function and resulting decreased accumulation of intracellular cGMP may decrease PDE5 protein expression through cGMPresponsive sequences in the PDE5 promoter [32] . These topics require further investigation.
The present study has several limitations. First, the study population comprised a small number of patients, partially because of our careful selection of patient groups. Second, we acknowledge that a post-RP patient group with minimal or no ED would have represented an interesting comparative group; however, it is not feasible in practice to obtain erectile tissue from patients without ED. Third, SHIM scores differ between patients with vasculogenic and those with post-RP ED (consistent with previous studies [33, 34] ), which reflects the extent of disease.
Finally, the limited amount of tissue precluded immunohistochemical studies, which would have provided illustrative images of evaluated molecular markers. An integrative model of molecular derangements in the erectile tissue of men with vasculogenic ED and post-RP ED is presented in Fig. 7 .
In conclusion, the present study provides evidence that the mechanisms of vasculogenic ED and post-RP ED in the human penis involve derangements in constitutive NOS function, PDE5 protein expression, and RhoA/ROCK activity, along with increased oxidative stress, which conceivably provide a molecular basis for chronically reduced NO bioavailability and smooth muscle contraction in these conditions of erectile impairment. Selective differences in PDE5 protein expression suggest there are distinct molecular mechanisms for these ED subtypes.
